Novel Drug Duo Preserves Bladder in Muscle-Invasive Cancer

Published Date: 10 Mar 2026

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant sacituzumab govitecan plus pembrolizumab, the SURE-02 trial finds.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists discover the 'roadmap' that aggressive cancer uses to spread

2.

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

3.

Who Bears the Cost of "Forever Chemical" Cleanup?

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

An Eye Surgeon's Unexpected Discovery of the "Before and After".


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot